- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Goserelin, Ribociclib, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Newport Beach, California • Westwood, Kansas + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the local directory fallback.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Capecitabine, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Newport Beach, California • Rochester, Minnesota + 2 more
- Conditions
- Newly Diagnosed and Recurrent Glioblastoma
- Interventions
- Temozolomide, [177Lu]Lu-NeoB, [68Ga]Ga-NeoB
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
- Conditions
- Metastatic Neuroendocrine Prostate Cancer
- Interventions
- Antiemetics & antinauseants, GnRH antagonists, Gonadotropin-releasing hormone (GnRH) analogues, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Metoclopramide, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, [177Lu]Lu-PSMA-617, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [68Ga]Ga-PSMA-11
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Omaha, Nebraska • New York, New York + 1 more